RGNX: חובות לטווח קצר של החברה REGENXBIO

REGENXBIO Inc. (RGNX) specializes in developing advanced treatments using genome and nucleic acid modification. Market dynamics for the securities on GURU.Markets show that the individual short-term debt metric is 0.04. The company relies on the development of NAV viral vectors and partnerships with major players to combat vision loss, aiming to bring innovative drugs to market.

REGENXBIO Inc. (RGNX) is developing a gene therapy ecosystem, leveraging patent protection for NAV Technology vectors to monetize licenses. An analysis of total short-term debt allows for an assessment of the company's current liquidity amid high capital expenditures. This metric measures the risk of cash flow gaps should operating revenues decline. A sharp increase in liabilities signals a funding shortage and creates potential for short positions. This indicator determines capital resilience to a sudden contraction in cash flow.